Combination therapy of dabrafenib plus trametinib in patients with BRAF V600E -mutated biliary tract cancer

摘要

cqvip:To the Editor: In the last decade, next-generation sequencing(NGS)-based molecular profiling has shed light on the molecular landscape of biliary tract cancer(BTC), revealing the presence of several potentially actionable mutations [1]. According to Clinical Trials.gov, there are at least 40 phase I to IV ongoing trials aimed at evaluating the role of targeted treatments in BTC, as monotherapy or in combination with other anticancer agents [2]. Early encouraging results have been observed with therapies targeting IDH mutations, FGFR fusions, HER family and, more recently, BRAF mutations [3].